

PrescQIPP work plan 2024-6 (two-year rolling work plan)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025	Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026
Anticholinergic burden	Update to existing bulletin. Addition of any new tools, e.g. MediChec to calculate ACB score, what further evidence is available. Deprescribing algorithms	C								
Asthma	Update to existing bulletin New inhalers, costs change regularly, include Wales update. More info on carbon-friendly inhalers, Trimbrow (with the LAMA glycopyrronium is now licenced for asthma). Can delete mention of MURS in community pharmacy etc. PQS, NICE asthma inhaler decision aid and use of biologics in secondary care. Develop a review tool for those patients prescribed triple therapy inhalers (for COPD or asthma) to enable assessment against current NICE and/or GOLD clinical guidance. Include any changes arising from NICE guidance due to be published July 2024.	C								
Covert administration	Update on LPS as still not come into force in place of DoLS. Consider SMR as first step in process. Consider any new references. Consider adding CQC recommendations for which information to record https://www.cqc.org.uk/guidance-providers/adult-social-care/covert-administration-medicines	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025	Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026
Emollients	Update to bulletins 228,239 and 240 and 181 combining care homes and emollients and fire risk guidance into one overarching emollients bulletin. Include self care, Include cost effective barrier creams (update to bulletin 181) and when to deprescribe emollients. Consider implementing risk assessments for assessing potential fire hazard risks. Available products and pricing. Update in line with new products and cost comparison charts, to fit with other new skin bulletins.	N								
Dental products on FP10	Update to include to include advice patients with cancer (caries prevention in head and neck cancer) and prescribing of artificial saliva products.	N								
Medicines formulary and shared care guidance development across integrated care systems	Update to include links to RMOC/NHSE shared care protocols published in 2022. Include shared care, long term plan.	N								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025	Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026
Medicines waste	To include the environmental impact of waste medicines rather than just cost. Patient facing campaign materials. Ensure covers medication waste in care homes and how this could be minimised. Link with sustainability strategy.	N								
Medicines without harm	Link in to national safety programme to avoid duplication	C								
NSAIDs	Update to include cost comparison charts. Could be refreshed and republished.	C								
Point of care testing	Update- consider community pharmacy testing and clear directions regarding genomic testing program	N								
Polypharmacy and deprescribing	NG56 key therapeutic topic indicators withdrawn. Add information from national overprescribing report. Update links and add new tools. Include frailty and cover good practice in patients with frailty and link to bulletin 331 medication reviews in patients with multi-morbidity which includes recommendations regarding frailty.	C								
PPI- long term safety and gastro-protection	Cost comparison charts, latest availability of H2RA. Link to deprescribing algorithms. Refresh and republish this if no new evidence. Link to NHSBSA medication safety dashboard gastroprotective data https://www.nhsbsa.nhs.uk/access-our-data-products/epact2/dashboards-and-specifications/medication-safety	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025	Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026
Commissioning medicines in service redesign	Update to incorporate new structures and landscape. Consider non-pharmacological options (pain, depression, insomnia) reducing polypharmacy	N								
Chronic pain	Update to bulletin 284. This is a priority as it's part of the National MO opportunities. Incorporate safety alerts. Include tapentadol. https://www.prescqipp.info/our-resources/bulletins/bulletin-284-chronic-pain/	C								
Medicines safety	Update to include valproate. Include more information from PSIRF https://www.prescqipp.info/our-resources/bulletins/bulletin-288-medicines-safety/	C								
Vitamins and minerals (including Vitamin D)	Review of cost effective options based on current prices. Guidance for care homes. Update post Covid 19. Place in therapy for the new once monthly vitamin D preparation. Cost comparison charts. Update with NICE B12 guidance. Link to bariatric surgery bulletin. Cover what is commissioned by NHSE https://www.prescqipp.info/our-resources/bulletins/bulletin-275-vitamin-d/ https://www.prescqipp.info/our-resources/bulletins/bulletin-296-vitamins-and-minerals/	C								
Inhaler carbon footprint	Update full resource. Continue with regular updates to attachment 1 as and when needed https://www.prescqipp.info/our-resources/bulletins/bulletin-295-inhaler-carbon-footprint/	N and D								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025	Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026
Oral nutritional supplements	Review prices and cost effective options. Update in line with National NHSE workstream. Review recipe books if needed. Add cost comparison charts. https://www.prescqipp.info/our-resources/bulletins/bulletin-261-oral-nutritional-supplements/	C								
PROP-List	Consider new devices that could be included such as mucus clearing devices. Scope other areas of limited clinical value. https://www.prescqipp.info/our-resources/bulletins/bulletin-235-prop-list/	N								
Neuropathic pain	Include NI position especially regarding pregabalin and include more information to discourage the use of tramadol/ place in therapy / risks etc. Safety advice re gabapentinoids. Include review of lidocaine plasters. https://www.prescqipp.info/our-resources/bulletins/bulletin-216-neuropathic-pain/	C								
UTIs - Prevention, recognition and management	Update in line with National guidance. Include community pharmacy first schemes. Methenamine (Hiprex) to be included in light of ALTAR trial(NICE reviewing). Educational slideset to include community pharmacy service and any key messages for them e.g. AMS. https://www.prescqipp.info/our-resources/bulletins/bulletin-277-prevention-recognition-and-management-of-utis/									
Menopause	Updated NICE guidance expected May 2024. Need advice on off-label use of products and use in breast cancer pts. Testosterone guidance- monitoring and dose adjustment. https://www.prescqipp.info/our-resources/bulletins/bulletin-299-menopause/	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025	Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026
Acute Kidney Injury- sick day guidance	Will be combined with the Implementing NICE guidance for CKD and AKI which will need updating in 2025/6 https://www.prescqipp.info/our-resources/bulletins/bulletin-260-acute-kidney-injury-aki-sick-day-guidance/ https://www.prescqipp.info/our-resources/bulletins/bulletin-281-implementing-nice-guidance-in-ckd-and-aki/	C								
Constipation	Cover risks e.g. can cause hospital admissions unnecessarily. Particularly with care homes patients. https://www.prescqipp.info/our-resources/bulletins/bulletin-272-constipation/	C								
Type 2 diabetes	Update to resources and review of new treatments- this will be scheduled in post December 2024 to align with NICE guidance publication	C								
Anticoagulation	Update to resources to incorporate generic apixaban- Include a guide to support switching patients to generic apixaban.	C								
Management of obesity	Implementation of updated NICE guidance on overweight and obesity management (expected March 2024). Resources will include treatment pathway and treatment choices including adults and children. Include review of new treatments being licensed. Appropriate use of online weight management services reflect NI position as we don't currently have specialist weight management services e.g. tier 3 and 4. Are there any QIPP opportunities. Cancer risk with GLP1's? GLP1's and Tirzepatide.	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)

Bulletin name	Scope	Category	Quality assurance process planned quarter							
			Q1 Apr - Jun 2024	Q2 Jul - Sep 2024	Q3 Oct - Dec 2024	Q4 Jan to Mar 2025	Q1 Apr - Jun 2025	Q2 Jul - Sep 2025	Q3 Oct - Dec 2025	Q4 Jan to Mar 2026
Insomnia	<p>NICE TA published October 2023 approving the drug daridorexant for insomnia. Concerns about abuse potential which is documented in studies, in the US it is a controlled substance. It's also novel in that it has been granted MHRA approval for long term use.</p> <p>Bulletin will focus on insomnia pathway and include update to hypnotics bulletin and use of Sleepio app that is proposed to be procured for all patients in England. Ensuring appropriate treatment pathways are in place and highlight cost pressure.</p>	C								
Maximising prescribing resources-update	Update Bulletin 327 maximising prescribing resources spreadsheet to include key current SGLT2 NICE TA cost pressures that are not currently included ie. SGLT2s for CKD; & SGLT2s for Heart failure.	N								
Treatment of migraine	Implementation of NICE guidance and evaluation of new treatments for migraine. Draft pathway development. Appropriate education tools for clinicians	C								

Categories key: Skills (S) QIPP (Q) Clinical (C) Non-clinical (N) Data (D)